No abstract

No abstract

SummaryPast reports have suggested that antiphospholipid (aPL) antibodies may emerge as a response to antipsychotics treatment, as a high prevalence of aPL antibodies in antipsychotics users has been observed. However, no control group of non-medicated psychiatric patients was included in these reports. In a cross sectional study we determined the prevalence of aPL antibodies in 333 psychiatric inpatients. We compared the proportions of positive aPL antibodytests between users and non-users of antipsychotics with adjustments for potential confounders. The proportion of antipsychotics users carrying at least one aPL antibody ranged from 10Á8% to 27Á0% compared with 6Á8% to 27Á2% in non-users (P = 0Á24, P = 0Á24) depending on the method of detection of lupus anticoagulant (LA). The prevalence of LA detected by dilute Russell viper venom time or partial thromboplastin time-LA was not different between antipsychotics users and non-users (8Á1% vs. 5Á4%, P = 0Á53 and 18Á4% vs. 18Á2%, P = 0Á22), as well as the prevalence of IgM and IgG anti-b2-glycoprotein-I antibodies, IgM and IgG anti-cardiolipin antibodies(3Á8% vs. 2Á0%, P = 0Á75, 0Á0% vs. 0Á0%, P = not applicable, 1Á1 vs. 1Á4%, P = 0Á91, 2Á7% vs. 3Á4%, P = 0Á71). In conclusion, aPL antibodies were frequently found in patients with psychiatric diseases and no significant increase in the prevalence of aPL antibodies was observed in antipsychotics users.

No abstract

French GPs tend to have a deficit in diagnostic knowledge and practice in detection and treatment of early schizophrenia. It seems important to provide GPs with continuing medical education (CME) on detection and management of early schizophrenia and to set up relevant specialized outpatient services.

No abstract

No abstract

No abstract